Literature DB >> 24314050

Preoperative predictors of renal function decline after radical nephroureterectomy for upper tract urothelial carcinoma.

Matthew Kaag1, Landon Trost, R Houston Thompson, Ricardo Favaretto, Vanessa Elliott, Shahrokh F Shariat, Alexandra Maschino, Emily Vertosick, Jay D Raman, Guido Dalbagni.   

Abstract

OBJECTIVES: To model renal function after radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC). To identify predictors of renal function decline after surgery, thereby allowing the identification of patients likely to be ineligible for cisplatin-based chemotherapy in the adjuvant setting. PATIENTS AND METHODS: We retrospectively identified 374 patients treated with RNU for UTUC at three centres between 1995 and 2010. Estimated glomerular filtration rate (eGFR) was calculated using Chronic Kidney Disease Epidemiology Collaboration equation before RNU and at early (1-5 months after RNU) and late (>5 months) time points after RNU. Only patients deemed eligible for cisplatin-based chemotherapy before RNU (preoperative glomerular filtration rate [GFR] ≥60 mL/min/1.73 m(2) ) were included. Multivariable analysis identified the preoperative predictors of eGFR after RNU at early postoperative and late postoperative time points.
RESULTS: A total of 163 patients had an eligible early post-RNU eGFR measurement and 172 had an eligible late eGFR measurement. The median eGFR declined by 32% and did not show a significant trend toward recovery over time (P = 0.4). On multivariable analysis preoperative eGFR and patient age were significantly associated with early and late postoperative eGFR, while Charlson comorbidity index score was significantly associated with late postoperative eGFR alone.
CONCLUSIONS: In patients with normal preoperative eGFR (≥60 mL/min/1.73 m(2) ), renal function decreases by one-third after RNU and does not show evidence of recovery over time. Elderly patients and those with pre-RNU eGFR closer to 60 mL/min/1.73 m(2) (lower eGFR in the present cohort) are more likely to be ineligible for adjuvant cisplatin-based chemotherapy regimens because of renal function loss after RNU.
© 2013 The Authors. BJU International © 2013 BJU International.

Entities:  

Keywords:  chemotherapy; chronic kidney disease; kidney; nephroureterectomy; transitional cell carcinoma; urothelial carcinoma

Mesh:

Year:  2014        PMID: 24314050     DOI: 10.1111/bju.12597

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  11 in total

1.  Renal function recovery after radical nephroureterectomy for upper tract urothelial carcinoma.

Authors:  Byron H Lee; Emily C Zabor; Daniel Tennenbaum; Helena Furberg; Nicole Benfante; Jonathan A Coleman; Edgar A Jaimes; Paul Russo
Journal:  World J Urol       Date:  2017-12-05       Impact factor: 4.226

2.  Urothelial cancer: Optimizing and integrating cisplatin-based chemotherapy across the disease spectrum.

Authors:  Jay D Raman
Journal:  Nat Rev Urol       Date:  2018-01-16       Impact factor: 14.432

Review 3.  Upper tract urothelial carcinoma: Paradigm shift towards nephron sparing management.

Authors:  Julia V Fiuk; Brad F Schwartz
Journal:  World J Nephrol       Date:  2016-03-06

4.  A critical prognostic analysis of neutrophil-lymphocyte ratio for patients undergoing nephroureterectomy due to upper urinary tract urothelial carcinoma.

Authors:  Mesut Altan; Hakan Bahadır Haberal; Bülent Akdoğan; Haluk Özen
Journal:  Int J Clin Oncol       Date:  2017-06-09       Impact factor: 3.402

5.  Changes in renal function after nephroureterectomy for upper urinary tract carcinoma: analysis of a large multicenter cohort (Radical Nephroureterectomy Outcomes (RaNeO) Research Consortium).

Authors:  Alessandro Tafuri; Michele Marchioni; Clara Cerrato; Andrea Mari; Riccardo Tellini; Katia Odorizzi; Alessandro Veccia; Daniele Amparore; Aliasger Shakir; Umberto Carbonara; Andrea Panunzio; Federica Trovato; Michele Catellani; Letizia M I Janello; Lorenzo Bianchi; Giacomo Novara; Fabrizio Dal Moro; Riccardo Schiavina; Elisa De Lorenzis; Paolo Parma; Sebastiano Cimino; Ottavio De Cobelli; Francesco Maiorino; Pierluigi Bove; Fabio Crocerossa; Francesco Cantiello; David D'Andrea; Federica Di Cosmo; Francesco Porpiglia; Pasquale Ditonno; Emanuele Montanari; Francesco Soria; Paolo Gontero; Giovanni Liguori; Carlo Trombetta; Guglielmo Mantica; Marco Borghesi; Carlo Terrone; Francesco Del Giudice; Alessandro Sciarra; Andrea Galosi; Marco Moschini; Shahrokh F Shariat; Marta Di Nicola; Andrea Minervini; Matteo Ferro; Maria Angela Cerruto; Luigi Schips; Vincenzo Pagliarulo; Alessandro Antonelli
Journal:  World J Urol       Date:  2022-10-06       Impact factor: 3.661

Review 6.  Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer.

Authors:  M N Pham; A B Apolo; M De Santis; M D Galsky; B C Leibovich; L L Pisters; A O Siefker-Radtke; G Sonpavde; G D Steinberg; C N Sternberg; S T Tagawa; A Z Weizer; M E Woods; M I Milowsky
Journal:  World J Urol       Date:  2016-06-24       Impact factor: 4.226

Review 7.  A systematic review and meta-analysis of oncological and renal function outcomes obtained after segmental ureterectomy versus radical nephroureterectomy for upper tract urothelial carcinoma.

Authors:  D Fang; T Seisen; K Yang; P Liu; X Fan; N Singla; G Xiong; L Zhang; X Li; L Zhou
Journal:  Eur J Surg Oncol       Date:  2016-08-25       Impact factor: 4.424

8.  Nomogram predicting renal insufficiency after nephroureterectomy for upper tract urothelial carcinoma in the Chinese population: exclusion of ineligible candidates for adjuvant chemotherapy.

Authors:  Dong Fang; Qifu Zhang; Xuesong Li; Cheng Qian; Gengyan Xiong; Lei Zhang; Xiaopeng Chen; Xiaoyu Zhang; Wei Yu; Zhisong He; Liqun Zhou
Journal:  Biomed Res Int       Date:  2014-08-10       Impact factor: 3.411

Review 9.  Perioperative chemotherapy in the management of high risk upper tract urothelial cancers.

Authors:  Matthew G Kaag
Journal:  Transl Androl Urol       Date:  2020-08

Review 10.  Upper urinary tract disease: what we know today and unmet needs.

Authors:  Romain Mathieu; Karim Bensalah; Ilaria Lucca; Aurélie Mbeutcha; Morgan Rouprêt; Shahrokh F Shariat
Journal:  Transl Androl Urol       Date:  2015-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.